Partners Group's Creditor Standoff Adds a Third Front to an Already Fraught Year

Partners Group's H1 2026 revenue fell 7% as performance fees dropped 39%; it weighs €200m injection amid €6bn debt maturities and CEO change.

The Swiss private markets firm is discovering that 2026 was never going to be a quiet year. A leadership transition, a sharp contraction in performance fees, and now a €6bn wall of maturing debt across three portfolio companies are converging into a single, messy narrative for investors to untangle.

At the centre of the latest headache sit Emeria SASU, Ammega Group and Breitling — three holdings whose combined borrowings come due in 2027 and 2028. Negotiations with lenders are already underway, and the numbers being discussed reveal a meaningful gap in expectations. Partners Group is reportedly weighing a €200m capital injection to support the businesses, while creditors are pushing for between €500m and €600m to reduce the debt burden. That shortfall between what the asset manager is willing to deploy and what the market is demanding is unlikely to resolve itself quietly.

A Fee Slide That Reshaped the Outlook

The refinancing talks land at an awkward moment. On Tuesday, the firm reported first-half 2026 revenues down 7 percent at CHF 1.12bn, with the damage concentrated in performance fees, which collapsed 39 percent to CHF 216m. Those success-based earnings now account for just 19 percent of total income, down from a far more comfortable contribution in prior periods.

The knock-on effects are visible across the income statement. EBITDA slipped 9 percent to CHF 706m, though the margin held steady at 63 percent. Net profit fell 13 percent to CHF 502m. Management fees, the more predictable engine of the business, continue to grind higher — up 6 percent to CHF 905m — while assets under management edged from $185bn to $186bn over the course of the half.

The guidance revision tells its own story. Partners Group has trimmed its 2026 expectation for performance fees as a share of total revenue to 20–25 percent, a notable step down from the previous range anchored at 25–40 percent. The full-year target for new capital commitments, however, remains untouched at $26bn–$32bn, suggesting the fundraising machine is still functioning even as the quality of earnings comes under scrutiny.

The Leadership Handover Adds Another Variable

Complicating the calculus is the impending change at the top. CEO David Layton, in the role since 2019, will step down at year-end and move into a position as Chief Investment Officer and chair of the investment committee from January 2027. Two long-serving executives are slated to take over as co-CEOs.

Markets tend to treat management succession at asset managers with caution, given how much of the franchise value rests on client trust in leadership. Layton's continued presence in an investment-focused capacity provides some continuity, but the new duo will need to demonstrate they can sustain the firm's dealmaking momentum while navigating the debt negotiations and fee pressure simultaneously.

That dealmaking has hardly stalled. Partners Group is in exclusive talks to acquire a majority stake in Aroma-Zone from Eurazeo, and has announced plans to buy a majority interest in AVK Power Solutions, a European provider of power supply systems for data centres, with an equity investment expected to exceed $1bn. Both transactions signal an appetite for growth even as the earnings base contracts.

What the Refinancing Wall Means for Shareholders

The three portfolio companies in question illustrate a broader challenge now rippling through private equity portfolios: leveraged buyouts executed in an era of cheap financing are coming due for refinancing at considerably higher rates. For Partners Group as an asset manager, this does not automatically translate into a multibillion-euro hit to the balance sheet. But it consumes management attention, tests client confidence, and may ultimately require fresh capital beyond what has been signalled.

The equity market has already delivered its verdict on the past several months. The shares changed hands at €731.20 recently, up roughly 2.3 percent on the prior session as part of a tentative recovery attempt. That rebound looks fragile: over seven trading days the stock has shed 8.8 percent, and it remains down 31 percent since the start of the year.

The path forward hinges on whether the performance fee erosion proves cyclical or structural. If valuation markdowns in underlying portfolios continue and additional evergreen funds drift into gating situations, the pressure on the share price could persist regardless of how smoothly the leadership transition unfolds. Should performance fees stabilise in the second half and the new co-CEOs execute the announced acquisition strategy without disruption, the stock has room to recover from its depressed levels.

The January 2027 handover will serve as the next concrete checkpoint — a moment to observe whether the new leadership duo pursues the existing acquisition roadmap with conviction or pivots strategically. Between now and then, the trajectory of performance fees and the outcome of the creditor talks at Emeria, Ammega and Breitling will determine which of the firm's many open questions carries the most weight for the share price.